Celltrion Inc.October 22, 2019

FDA 483 - Celltrion Inc. - October 22, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Celltrion Inc.

Record Details

An FDA inspection of Celltrion Inc., a sterile pharmaceutical manufacturer in Incheon, Korea, revealed a significant deficiency in aseptic processing areas. The firm's dynamic airflow visualization studies for its restricted access barrier system were found to be inadequate, failing to properly visualize airflow at critical areas during simulated interventions. This indicates a potential risk to the sterility of parenteral drug products.

Company: Celltrion Inc.
Inspection Date: October 22, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Matthew B. Casale ( Investigator )

Open in Dashboard

ID · 57f6ed48-3c6c-4460-80ee-647bd64b5189